ANTISARSCOV2.: Development and production of anti-SARS-CoV-2 antibodies intended for the investigation of COVID19 (Q2867184)

From EU Knowledge Graph
Revision as of 10:29, 13 September 2021 by DG Regio (talk | contribs) (‎Removed claim: co-financing rate (P837): 76.0 percent, Removing co-finance rate from projects in portugal)
Jump to navigation Jump to search
Project Q2867184 in Portugal
Language Label Description Also known as
English
ANTISARSCOV2.: Development and production of anti-SARS-CoV-2 antibodies intended for the investigation of COVID19
Project Q2867184 in Portugal

    Statements

    0 references
    329,906.98 Euro
    0 references
    1 June 2020
    0 references
    31 December 2020
    0 references
    SICGEN - INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA LDA
    0 references
    0 references

    40°1'45.98"N, 8°23'24.86"W
    0 references
    A SICGEN é uma empresa especializada na produção de anticorpos. Tem em curso projetos relacionados com pandemia atual, que envolvem a produção de anticorpos que podem ser usados em investigação, na produção de kits por laboratórios e por empresas de biotecnologia para auxiliar a combate à Covid-19. (Portuguese)
    0 references
    SICGEN is a company specialised in the production of antibodies. It has ongoing projects related to the current pandemic, involving the production of antibodies that can be used in research, in the production of kits by laboratories and biotechnology companies to assist in the fight against Covid-19. (English)
    7 July 2021
    0 references
    Penela
    0 references

    Identifiers

    CENTRO-01-02B7-FEDER-069378
    0 references